{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T04:31:39Z","timestamp":1722573099449},"reference-count":50,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2002,3,1]]},"abstract":"<jats:p>PURPOSE: CD20 can be expressed in Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin\u2019s disease (HD), but its clinical significance remains controversial. Therefore, we correlated CD20 expression with presenting features and clinical outcome of untreated patients with classical HD.<\/jats:p><jats:p>PATIENTS AND METHODS: Patients were eligible if they were previously untreated and human immunodeficiency virus-1 negative, had biopsy-proven classical HD, and if pretreatment paraffin-embedded tumor tissue was available. CD20 expression was determined by immunohistochemistry without knowledge of clinical outcome. A tumor was considered positive if any HRS cells expressed CD20, but other cutoffs for number of CD20-positive HRS were also investigated.<\/jats:p><jats:p>RESULTS: We identified 598 patients whose median age was 30 years and of whom 55% were male. HRS cells expressed CD20 in 132 (22%) of 598 patients with classical HD. When any percentage of CD20 expression in HRS cells was used as a cutoff, the 5-year failure-free survival (FFS) for positive versus negative tumors was 86% versus 84%, respectively, for 302 patients treated with doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent regimens (P = .7 by log-rank test), 74% versus 77%, respectively, for 181 patients treated with mitoxantrone, vincristine, vinblastine, and prednisone and radiotherapy (P = .7 by log-rank test), 74% versus 84%, respectively, for 54 patients treated with MOPP (P = .4 by log-rank test), and 77% versus 88% for 53 patients treated only with radiotherapy (P = .5 by log-rank test). The 5-year FFS was not statistically different when cutoffs of 5% up to 50% for CD20-positive HRS cells were used.<\/jats:p><jats:p>CONCLUSION: CD20 is expressed by HRS cells in 22% of patients with classical HD but is not associated with different FFS after treatment with equivalent regimens.<\/jats:p>","DOI":"10.1200\/jco.2002.20.5.1278","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T08:51:36Z","timestamp":1487926296000},"page":"1278-1287","source":"Crossref","is-referenced-by-count":4,"title":["CD20 Expression in Hodgkin and Reed-Sternberg Cells of Classical Hodgkin\u2019s Disease: Associations With Presenting Features and Clinical Outcome"],"prefix":"10.1200","volume":"20","author":[{"given":"George Z.","family":"Rassidakis","sequence":"first","affiliation":[{"name":"From the Departments of Lymphoma-Myeloma and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Departments of Medical Oncology and Pathology, Istituto Tumori, Milan, and Departments of Hematology and Pathology, University of Verona, Verona, Italy; and First Department of Internal Medicine and Laboratory of Histology and Embryology, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma-Myeloma and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Departments of Medical Oncology and Pathology, Istituto Tumori, Milan, and Departments of Hematology and Pathology, University of Verona, Verona, Italy; and First Department of Internal Medicine and Laboratory of Histology and Embryology, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simonetta","family":"Viviani","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma-Myeloma and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Departments of Medical Oncology and Pathology, Istituto Tumori, Milan, and Departments of Hematology and Pathology, University of Verona, Verona, Italy; and First Department of Internal Medicine and Laboratory of Histology and Embryology, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Bonfante","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma-Myeloma and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Departments of Medical Oncology and Pathology, Istituto Tumori, Milan, and Departments of Hematology and Pathology, University of Verona, Verona, Italy; and First Department of Internal Medicine and Laboratory of Histology and Embryology, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian-Paolo","family":"Nadali","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma-Myeloma and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Departments of Medical Oncology and Pathology, Istituto Tumori, Milan, and Departments of Hematology and Pathology, University of Verona, Verona, Italy; and First Department of Internal Medicine and Laboratory of Histology and Embryology, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodoros P.","family":"Vassilakopoulos","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma-Myeloma and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Departments of Medical Oncology and Pathology, Istituto Tumori, Milan, and Departments of Hematology and Pathology, University of Verona, Verona, Italy; and First Department of Internal Medicine and Laboratory of Histology and Embryology, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofelia","family":"Mesina","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma-Myeloma and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Departments of Medical Oncology and Pathology, Istituto Tumori, Milan, and Departments of Hematology and Pathology, University of Verona, Verona, Italy; and First Department of Internal Medicine and Laboratory of Histology and Embryology, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Herling","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma-Myeloma and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Departments of Medical Oncology and Pathology, Istituto Tumori, Milan, and Departments of Hematology and Pathology, University of Verona, Verona, Italy; and First Department of Internal Medicine and Laboratory of Histology and Embryology, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria K.","family":"Angelopoulou","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma-Myeloma and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Departments of Medical Oncology and Pathology, Istituto Tumori, Milan, and Departments of Hematology and Pathology, University of Verona, Verona, Italy; and First Department of Internal Medicine and Laboratory of Histology and Embryology, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Giardini","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma-Myeloma and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Departments of Medical Oncology and Pathology, Istituto Tumori, Milan, and Departments of Hematology and Pathology, University of Verona, Verona, Italy; and First Department of Internal Medicine and Laboratory of Histology and Embryology, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Chilosi","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma-Myeloma and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Departments of Medical Oncology and Pathology, Istituto Tumori, Milan, and Departments of Hematology and Pathology, University of Verona, Verona, Italy; and First Department of Internal Medicine and Laboratory of Histology and Embryology, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Kittas","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma-Myeloma and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Departments of Medical Oncology and Pathology, Istituto Tumori, Milan, and Departments of Hematology and Pathology, University of Verona, Verona, Italy; and First Department of Internal Medicine and Laboratory of Histology and Embryology, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma-Myeloma and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Departments of Medical Oncology and Pathology, Istituto Tumori, Milan, and Departments of Hematology and Pathology, University of Verona, Verona, Italy; and First Department of Internal Medicine and Laboratory of Histology and Embryology, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Alma","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma-Myeloma and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Departments of Medical Oncology and Pathology, Istituto Tumori, Milan, and Departments of Hematology and Pathology, University of Verona, Verona, Italy; and First Department of Internal Medicine and Laboratory of Histology and Embryology, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Romaguera","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma-Myeloma and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Departments of Medical Oncology and Pathology, Istituto Tumori, Milan, and Departments of Hematology and Pathology, University of Verona, Verona, Italy; and First Department of Internal Medicine and Laboratory of Histology and Embryology, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianni","family":"Bonadonna","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma-Myeloma and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Departments of Medical Oncology and Pathology, Istituto Tumori, Milan, and Departments of Hematology and Pathology, University of Verona, Verona, Italy; and First Department of Internal Medicine and Laboratory of Histology and Embryology, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro M.","family":"Gianni","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma-Myeloma and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Departments of Medical Oncology and Pathology, Istituto Tumori, Milan, and Departments of Hematology and Pathology, University of Verona, Verona, Italy; and First Department of Internal Medicine and Laboratory of Histology and Embryology, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Pizzolo","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma-Myeloma and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Departments of Medical Oncology and Pathology, Istituto Tumori, Milan, and Departments of Hematology and Pathology, University of Verona, Verona, Italy; and First Department of Internal Medicine and Laboratory of Histology and Embryology, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerassimos A.","family":"Pangalis","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma-Myeloma and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Departments of Medical Oncology and Pathology, Istituto Tumori, Milan, and Departments of Hematology and Pathology, University of Verona, Verona, Italy; and First Department of Internal Medicine and Laboratory of Histology and Embryology, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Cabanillas","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma-Myeloma and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Departments of Medical Oncology and Pathology, Istituto Tumori, Milan, and Departments of Hematology and Pathology, University of Verona, Verona, Italy; and First Department of Internal Medicine and Laboratory of Histology and Embryology, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas H.","family":"Sarris","sequence":"additional","affiliation":[{"name":"From the Departments of Lymphoma-Myeloma and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Departments of Medical Oncology and Pathology, Istituto Tumori, Milan, and Departments of Hematology and Pathology, University of Verona, Verona, Italy; and First Department of Internal Medicine and Laboratory of Histology and Embryology, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-103959","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.9.1295"},{"key":"R3-103959","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199211193272102"},{"key":"R4-103959","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.7.1173"},{"key":"R5-103959","doi-asserted-by":"publisher","DOI":"10.3109\/10428199209061558"},{"key":"R6-103959","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509052700"},{"key":"R7-103959","unstructured":"Ferme C, Lepage E, Bastion Y, et al: Advanced Hodgkin\u2019s disease: Validation of the MSKCC prognostic model. How to identify a high-risk group qualifying for intensive initial treatment? The GELA study. Ann Oncol 7: 112,1996 (suppl 3, abstr)"},{"key":"R8-103959","unstructured":"Sarris AH, Straus D, Preti A, et al: A prognostic model for advanced Hodgkin\u2019s Disease at M.D. Anderson validated with an independent set of patients treated at Memorial Sloan-Kettering. Blood 88: 893a,1996 (suppl 1, abstr)"},{"key":"R9-103959","unstructured":"Sarris A, Daliani D, Mesina O, et al: A prognostic model for failure-free survival (FFS) of adults with clinical Ann Arbor stage (AAS) I\/II Hodgkin\u2019s disease (HD) after combined modality therapy. Proc Am Soc Clin Oncol 16: 7a,1997 (abstr 23)"},{"key":"R10-103959","unstructured":"Sarris A, Preti A, Mesina O, et al: A predictive model for failure-free survival (FFS) of adults with Hodgkin\u2019s disease treated with ABVD or equivalent regimens. Blood 90: 388a,1997 (suppl 1, abstr)"},{"key":"R11-103959","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392104"},{"key":"R12-103959","doi-asserted-by":"crossref","unstructured":"Sarris AH, Kliche KO, Pethambaram P, et al: Interleukin-10 levels are often elevated in serum of adults with Hodgkin\u2019s disease and are associated with inferior failure-free survival. Ann Oncol 10: 1,1999-8,","DOI":"10.1023\/A:1008301602785"},{"key":"R13-103959","doi-asserted-by":"publisher","DOI":"10.1007\/BF02787350"},{"key":"R14-103959","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050564"},{"key":"R15-103959","unstructured":"Vassilakopoulos TP, Nadali G, Angelopoulou MK, et al: Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin\u2019s lymphoma. Haematologica 86: 274,2001-281,"},{"key":"R16-103959","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.16.1.471"},{"key":"R17-103959","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708143370703"},{"key":"R18-103959","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708143370704"},{"key":"R19-103959","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199510053331403"},{"key":"R20-103959","unstructured":"Pinkus GS, Said JW: Hodgkin\u2019s disease, lymphocyte predominance type, nodular: Further evidence for a B cell derivation. L & H variants of Reed-Sternberg cells express L26, a pan B cell marker. Am J Pathol 133: 211,1988-217,"},{"key":"R21-103959","unstructured":"Schmid C, Pan L, Diss T, et al: Expression of B-cell antigens by Hodgkin\u2019s and Reed-Sternberg cells. Am J Pathol 139: 701,1991-707,"},{"key":"R22-103959","unstructured":"Zukerberg LR, Collins AB, Ferry JA, et al: Coexpression of CD15 and CD20 by Reed-Sternberg cells in Hodgkin\u2019s disease. Am J Pathol 139: 475,1991-483,"},{"key":"R23-103959","unstructured":"Chu WS, Abbondanzo SL, Frizzera G: Inconsistency of the immunophenotype of Reed-Sternberg cells in simultaneous and consecutive specimens from the same patients: A paraffin section evaluation in 56 patients. Am J Pathol 141: 11,1992-17,"},{"key":"R24-103959","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1993.tb00173.x"},{"key":"R25-103959","doi-asserted-by":"publisher","DOI":"10.1002\/path.1711740108"},{"key":"R26-103959","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/108.1.54"},{"key":"R27-103959","unstructured":"von Wasielewski R, Mengel M, Fischer R, et al: Classical Hodgkin\u2019s disease: Clinical impact of the immunophenotype. Am J Pathol 151: 1123,1997-1130,"},{"key":"R28-103959","doi-asserted-by":"crossref","unstructured":"Korkolopoulou P, Cordell J, Jones M, et al: The expression of the B-cell marker mb-1 (CD79a) in Hodgkin\u2019s disease. Histopathology 24: 511,1994-515,","DOI":"10.1111\/j.1365-2559.1994.tb00568.x"},{"key":"R29-103959","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.9.3108"},{"key":"R30-103959","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.4.1308"},{"key":"R31-103959","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1988.tb02867.x"},{"key":"R32-103959","doi-asserted-by":"crossref","unstructured":"Tedder TF, Klejman G, Schlossman SF, et al: Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1). J Immunol 142: 2560,1989-2568,","DOI":"10.4049\/jimmunol.142.7.2560"},{"key":"R33-103959","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(94)90276-3"},{"key":"R34-103959","unstructured":"von Wasielewski R, Werner M, Fischer R, et al: Lymphocyte-predominant Hodgkin\u2019s disease: An immunohistochemical analysis of 208 reviewed Hodgkin\u2019s disease cases from the German Hodgkin Study Group. Am J Pathol 150: 793,1997-803,"},{"key":"R35-103959","unstructured":"Anagnostopoulos I, Hansmann ML, Franssila K, et al: European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: Histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 96: 1889,2000-1899,"},{"key":"R37-103959","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"R38-103959","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"R39-103959","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.1.101"},{"key":"R40-103959","unstructured":"Coiffier B, Lepage E, Herbrecht R, et al: Mabthera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim results of a randomized GELA trial. Blood 96: 223a,2000 (abstr)"},{"key":"R41-103959","unstructured":"Lukas JB, Hoppe RT, Horwitz SM, et al: Rituximab is active in lymphocyte predominance Hodgkin\u2019s disease. Blood 96: 508a,2000 (abstr)"},{"key":"R42-103959","unstructured":"Donnelly GB, Filippa D, Moskowitz CH, et al: Increased treatment failure in patients with CD20 positive classic Hodgkin\u2019s disease (HD). Blood 94: 2662,1999 (part 1, suppl 1, abstr)"},{"key":"R43-103959","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"R45-103959","unstructured":"Carbone PP, Kaplan HS, Musshoff K, et al: Report of the committee on Hodgkin\u2019s disease staging classification. Cancer Res 31: 1860,1971-1861,"},{"key":"R46-103959","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-104-6-739"},{"key":"R47-103959","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009057636"},{"key":"R48-103959","doi-asserted-by":"crossref","unstructured":"Hagemeister FB, Fuller L, McLaughlin P, et al: NOVP and radiotherapy for early-staged Hodgkin\u2019s disease: An interim analysis. Ann Oncol 4: 87,1992-90,","DOI":"10.1093\/annonc\/3.suppl_4.S87"},{"key":"R49-103959","unstructured":"Viviani S, Bonfante V, Santoro A, et al: Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin\u2019s disease. Cancer J Sci Am 5: 275,1999-282,"},{"key":"R50-103959","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)61724-5"},{"key":"R51-103959","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501440"},{"key":"R52-103959","unstructured":"Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163,1966-170,"},{"key":"R53-103959","doi-asserted-by":"publisher","DOI":"10.1084\/jem.179.4.1099"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2002.20.5.1278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T10:33:50Z","timestamp":1692700430000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2002.20.5.1278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3,1]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,3,1]]}},"alternative-id":["10.1200\/JCO.2002.20.5.1278"],"URL":"https:\/\/doi.org\/10.1200\/jco.2002.20.5.1278","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3,1]]}}}